The North America Organ-on-Chip Market would witness market growth of 29.4% CAGR during the forecast period (2022-2028).
Organ-on-a-chip is a captivating scientific and technological advancement that combines biology and microtechnology to simulate essential aspects of human physiology. The chip is a microfluidic device with networks of hair-thin micro-channels for directing and manipulating minute quantities of solution. The organ is a more applicable name for the small tissues generated and housed on microfluidic chips, which can mimic one or more tissue-specific functionalities.
A significant number of researchers have discovered that while being far simpler than actual tissues and organs, these systems may often function as good models of human physiology and illness. OOCs consists of cutting-edge in vitro technology that permits the testing and evaluation of biological tissues and cells outside the body. This is accomplished by enclosing the cells within biochemically and physically similar vessels to the in vivo environment.
Working at the microscale provides a unique chance to achieve more control over the micro-ecosystem that sustains tissue life, as well as a tool to directly study cell and tissue behavior. A form of artificial organ, an organ-on-a-chip (OOC) is a multi-channel, three-dimensional cell culture integrated circuit (chip) that simulates the activities, mechanics, and physiological response of an entire organ or organ system. It is the topic of extensive biomedical engineering study, more specifically in bio-MEMS.
The R&D industry of regional countries is robust while also growing stronger rapidly. The market is primarily driven by a rise in research and development (R&D) activities, an increase in vaccine trials, the demand for personalized medicine, as well as the growing use of new technologies. Virtual trials were highly conducted within the United States as they can significantly reduce the time, effort, and strain on volunteers, researchers, and clinical research coordinators. The rapid adoption of new technology for enhanced healthcare is one of the most influential elements in the nature of competition. All of these factors are contributing to the increased growth of the regional market.
The US market dominated the North America Organ-on-Chip Market by Country in 2021; thereby, achieving a market value of $237,085.6 Thousands by 2028. The Canada market is experiencing a CAGR of 32.3% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 31.2% during (2022 - 2028).
Based on Type, the market is segmented into Lung on chip, Heart on chip, Human on chip, Kidney on chip, Liver on chip, and Intestine on chip. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Organ-on-Chip Market is Predict to reach $815.6 Million by 2028, at a CAGR of 30.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AxoSim, Inc., Visikol, Inc., CN Bio Innovations Limited., Elveflow (Elvesys Group), Emulate, Inc., Insphero AG, Mimetas B.V., Nortis Inc., Organovo Holdings, Inc. and TARA Biosystems, Inc.
By Type
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.